Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes (NCT00413751) | Clinical Trial Compass
CompletedNot Applicable
Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes
United States20 participants
Plain-language summary
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
Who can participate
Age range18 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.
Exclusion Criteria:
* Patients not meeting above stated age criteria
* Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
* History of serious ocular, neurological, cardiovascular disease
* History of severe systemic disease
* History of arrhythmias or high blood pressure
* Patients currently taking any type of ocular or systemic medications except multivitamins.
* Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.